Vaiomer has established itself as a specialized service provider and technology leader in the challenging field of low bacterial biomass microbiome analysis, with a core focus on blood and tissue samples. The company's proprietary, contamination-controlled metagenomic workflow allows researchers to accurately profile microbiota outside the gut, unlocking insights into systemic inflammation, bacterial translocation, and their roles in chronic diseases. By collaborating with academic and research institutions globally, Vaiomer generates compelling data that fuels discovery across cardiometabolic, neurodegenerative, oncological, and infectious diseases, positioning itself as a critical enabler for next-generation microbiome research.
Cardio-metabolic diseasesLiver diseasesGastrointestinal disordersCancerNeurodegenerative and mental disordersCOVID, HIV & infectious diseasesAutoimmune and inflammatory diseasesNutritionKidney diseases
Technology Platform
Proprietary, contamination-aware metagenomic workflow specifically optimized for the disruption, extraction, sequencing, and bioinformatic analysis of low bacterial biomass samples from blood and tissues.
Funding History
3
Total raised:$26M
Series B$15MSofinnova Partners
Series A$8.5MSofinnova Partners
Seed$2.5MUndisclosed
Opportunities
The primary opportunity lies in the vast, untapped potential of the systemic microbiome as a new frontier for biomarker discovery and therapeutic target identification across chronic diseases.
As the field gains acceptance, Vaiomer is positioned to become the essential partner for pharma companies integrating microbiome analysis into drug development, particularly in immuno-oncology and inflammatory diseases.
Long-term, its unique datasets could enable the development of novel, minimally invasive diagnostic tests based on blood microbiome signatures.
Risk Factors
Key risks include ongoing scientific debate about the biological significance of low-biomass microbiomes, which could slow market adoption.
The company faces potential competition from larger, well-funded genomics service providers that could develop similar expertise.
Its service-based model, while generating revenue, may offer limited upside compared to owning therapeutic or diagnostic products, creating a scalability and valuation challenge.
Competitive Landscape
Vaiomer operates in a specialized niche with few direct competitors focused solely on low-biomass tissue and blood analysis. It faces indirect competition from large CROs and sequencing service providers (e.g., Eurofins, Novogene) that offer broader metagenomic services but may lack equivalent contamination-control expertise. Other microbiome analytics firms are typically focused on gut, skin, or oral samples, leaving Vaiomer with a distinct first-mover advantage in its chosen segment.
